85302-08-5

Basic information

• Product Name: 2-[(dimethylamino)methylidene]-5-phenylcyclohexane-1,3-dione
• Synonyms: 2-[(dimethylamino)methylidene]-5-phenylcyclohexane-1,3-dione;2-((dimethylamino)methylene)-5-phenylcyclohexane-1,3-dione
• CAS NO: 85302-08-5
• Molecular Formula: C₁₅H₁₇NO₂
• Molecular Weight: 243.30098
• EINECS: -0
• Mol File: 85302-08-5.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[(dimethylamino)methylidene]-5-phenylcyclohexane-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(dimethylamino)methylidene]-5-phenylcyclohexane-1,3-dione(85302-08-5)
• EPA Substance Registry System: 2-[(dimethylamino)methylidene]-5-phenylcyclohexane-1,3-dione(85302-08-5)

Safety Data

• Hazardous Substances Data: 85302-08-5(Hazardous Substances Data)

Upstream product

• 100-52-7 benzaldehyde 
• 100-51-6 benzyl alcohol 
• 122-57-6 1-Phenylbut-1-en-3-one 
• 493-72-1 5-phenyl-cyclohexane-1,3-dione 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 85302-18-7 1-Methyl-6-phenyl-1,5,6,7-tetrahydro-indazol-4-one 
• 155857-93-5 2-[(3-Hydroxy-propylamino)-methylene]-5-phenyl-cyclohexane-1,3-dione 
• 29974-44-5 5-phenyl-2-((phenylamino)methylene)-cyclohexane-1,3-dione 
• 64500-68-1 2-(hydroxymethylene)-5-phenylcyclohexane-1,3-dione 

Relevant articles and documents

Inhibition studies on carbonic anhydrase isoforms I, II, IV and IX with N-arylsubstituted secondary sulfonamides featuring a bicyclic tetrahydroindazole scaffold

Carbonic Anhydrases (CAs) are pharmaceutically relevant targets for the treatment of several disease conditions. The ubiquitous localization of these enzymes and the high homology shared by the different isoforms represent substantial impediments for the

Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein

The autophagic ubiquitin-like protein LC3 functions through interactions with LC3-interaction regions (LIRs) of other autophagy proteins, including autophagy receptors, which stands out as a promising protein–protein interaction (PPI) target for the intervention of autophagy. Post-translational modifications like acetylation of Lys49 on the LIR-interacting surface could disrupt the interaction, offering an opportunity to design covalent small molecules interfering with the interface. Through screening covalent compounds, we discovered a small molecule modulator of LC3A/B that covalently modifies LC3A/B protein at Lys49. Activity-based protein profiling (ABPP) based evaluations reveal that a derivative molecule DC-LC3in-D5 exhibits a potent covalent reactivity and selectivity to LC3A/B in HeLa cells. DC-LC3in-D5 compromises LC3B lipidation in vitro and in HeLa cells, leading to deficiency in the formation of autophagic structures and autophagic substrate degradation. DC-LC3in-D5 could serve as a powerful tool for autophagy research as well as for therapeutic interventions.

USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND

The present invention relates to use of an aminomethylenecyclohexane-1,3-dione compound, more particularly to use of a compound shown in the following formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with other drug in pre